Aerpio Pharmaceuticals (Aerpio Pharmaceuticals) Scaled Net Operating Assets : -0.04 (As of Jun. 2021)

View and export this data going back to 2017. Start your Free Trial

What is Aerpio Pharmaceuticals Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Aerpio Pharmaceuticals's operating assets for the quarter that ended in Jun. 2021 was $0.61 Mil. Aerpio Pharmaceuticals's operating liabilities for the quarter that ended in Jun. 2021 was $2.20 Mil. Aerpio Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2021 was $41.16 Mil. Therefore, Aerpio Pharmaceuticals's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2021 was -0.04.

Aerpio Pharmaceuticals Scaled Net Operating Assets Historical Data

The historical data trend for Aerpio Pharmaceuticals's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aerpio Pharmaceuticals Scaled Net Operating Assets Chart

Aerpio Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Scaled Net Operating Assets

Get a 7-Day Free Trial

-3,973.26

-1.18

-0.19

-0.03

0.01

Aerpio Pharmaceuticals Quarterly Data
	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21
Scaled Net Operating Assets	Get a 7-Day Free Trial															-0.06	-	0.01	-	-0.04

Competitive Comparison of Aerpio Pharmaceuticals's Scaled Net Operating Assets

For the Biotechnology subindustry, Aerpio Pharmaceuticals's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aerpio Pharmaceuticals's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aerpio Pharmaceuticals's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Aerpio Pharmaceuticals's Scaled Net Operating Assets falls into.

Aerpio Pharmaceuticals Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Aerpio Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2020 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2020 )
=	(Operating Assets (A: Dec. 2020 )	-	Operating Liabilities (A: Dec. 2020 ))	/	Total Assets (A: Dec. 2019 )
=	(2.32	-	1.8)	/	39.937
=	0.01

where

	Operating Assets		(A: Dec. 2020 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	44.925	-	42.605
=	2.32

	Operating Liabilities		(A: Dec. 2020 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	1.867	-	0	-	0.067
=	1.8

Aerpio Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the quarter that ended in Jun. 2021 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Jun. 2021 )
=	(Operating Assets (Q: Jun. 2021 )	-	Operating Liabilities (Q: Jun. 2021 ))	/	Total Assets (Q: Mar. 2021 )
=	(0.608	-	2.198)	/	41.161
=	-0.04

where

	Operating Assets		(Q: Jun. 2021 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	37.424	-	36.816
=	0.608

	Operating Liabilities		(Q: Jun. 2021 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	2.208	-	0	-	0.01
=	2.198

Aerpio Pharmaceuticals Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Aerpio Pharmaceuticals's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Aerpio Pharmaceuticals (Aerpio Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aerpio Pharmaceuticals Inc (NAS:ARPO) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

9987 Carver Road, Cincinnati, OH, USA, 45242

Website

https://www.aerpio.com

Aerpio Pharmaceuticals Inc is a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases. The company's product razuprotafib is a small molecule Tie2 activator being developed for the topical ocular treatment of primary open-angle glaucoma. Other products under the pipeline are ARP-1536 and AKB-4924.

Executives

Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Pravin Dugel	director	C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, CINCINNATI OH 45242
Caley Castelein	director	THOM. WEISEL HEALTHCARE VENTURES, ONE MONTGOMERY STREET, SAN FRANCISCO CA 94104
Anupam Dalal	director	88 KEARNY STREET, SUITE 1800, SAN FRANCISCO CA 94108
Cheryl Cohen	director	C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105
Steven Prelack	director	7 WHEELWRIGHT ROAD, MEDFIELD MA 02052
Regina Marek	officer: Vice President of Finance	C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, SUITE 420, CINCINNATI OH 45242
Joseph H. Gardner	director, officer: President	C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, CINCINNATI OH 45242
Kevin G. Peters	officer: See Remarks	C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, C OH 45242
Muneer A Satter	director, 10 percent owner	C/O SATTER INVESTMENT MANAGEMENT, LLC, 676 NORTH MICHIGAN AVENUE, SUITE 4000, CHICAGO IL 60611
Chau Quang Khuong	director, 10 percent owner	C/O ORBIMED ADVISORS, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Michael W Rogers	officer: See Remarks	C/O KERYX BIOPHARMACEUTICALS INC, ONE MARINA PARK DRIVE, BOSTON MA 02210
Stephen J Hoffman	director, officer: Chief Executive Officer	C/O SKYLINE VENTURES, 525 UNIVERSITY AVE., SUITE 1350, PALO ALTO CA 94301
Novartis Bioventures Ltd	10 percent owner	C/O NOVARTIS INTERNATIONAL AG, WSJ-200.220, CH-4002 BASEL V8 0000000000
Ag Novartis	10 percent owner	LICHTSTRASSE 35, BASEL V8 CH 4056